Cynata Therapeutics Limited · ASX:CYP
Cynata Therapeutics — Investor Presentation (September 2024)
23 slides from Cynata Therapeutics's investor presentation, Sep 5, 2024
Slide 1: ASX Announcement: Investor Webinar
ASX ANNOUNCEMENT 5 September 2024 Investor Webinar Melbourne, Australia; 5 September 2024: Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, reminds shareholders that CEO and Managing Director, Dr Kilian Ke
Slide 2: A Clinical Stage Next Generation Stem Cell Therapeutics Company
For personal use only A Clinical Stage Next Generation Stem Cell Therapeutics Company Investor Webinar 5 September 2024
Slide 3: Important information
Important information Summary information This Presentation contains summary information about Cynata Therapeutics Limited and its subsidiaries Forward-looking statements (CYP, or Cynata) which is current as at 5 September 2024. This Presentation should be read in This Presentation contains certain
Slide 4: Company highlights
Company highlights Revolutionary Cymerus manufacturing platform For personal use only • Mesenchymal stem cells (MSCs)1 have shown potential to treat a wide range of illnesses2 • However, standard manufacture requires ongoing supply of donors → challenges with consistency, potency and scale • The ind
Slide 5: FY 2024 – a year of progress
FY 2024 – a year of progress Multiple clinical trials advanced • Phase 3 osteoarthritis trial – patient enrolment completed in November 2023 For personal use only • Global Phase 2 aGvHD trial – first patient enrolled in March 2024 • Phase 1 DFU trial – patient enrolment completed in April 2024 • New
Slide 6: Advanced and diverse clinical pipeline
Advanced and diverse clinical pipeline Indication Trial phase Upcoming catalysts* Market opportunity For personal use only Acute Graft vs Host Disease (aGvHD) Enrolment completion – Q4 2024 Phase 2 Cynata Sponsored CYP-001 US$600m1 FDA Orphan Designation ongoing Results – 2H 2025 Phase 1 Diabetic Fo
Slide 7: Revolutionary iPSC-based Cymerus Manufacturing Platform
For personal use only Revolutionary iPSC-based Cymerus Manufacturing Platform
Slide 8: Therapeutic potential of MSCs
Therapeutic potential of MSCs Mesenchymal stem cells1 (MSCs): • Promote an immunomodulatory For personal use only environment2 • The “sensor and switcher of the immune system”3 • Promote tissue repair and regeneration • Can be used without matching donors to recipients • Can be engineered to express
Slide 9: Advantages of iPSC-based platform
Advantages of iPSC-based platform Induced pluripotent stem cells (iPSCs): For personal use only • Mature adult cells reprogrammed to become pluripotent, which means: • Effectively limitless proliferation capacity • Potential to differentiate into any adult cell type (including MSCs) • Similar proper
Slide 10: Conventional MSC process vs Cymerus iPSC-based process
Conventional MSC process Major challenges: Ongoing need • MSCs undergo functional changes MSC isolation Culture expansion and loss of potency during for new donors extensive culture expansion • Continuously finding and testing new For personal use only donors is logistically challenging • Inter-dono
Slide 11: Partnering Strategy
For personal use only Partnering Strategy
Slide 12: Commercial partnering
Commercial partnering Commercial partnering potential underpinned by: (i) compelling clinical For personal use only data; and (ii) scalable, commercial grade manufacturing platform Several distinct products in development → potential for multiple partnerships Platform also available to partners purs
Slide 13: Industry connections
Industry connections • We are enhancing our individual outreach to selected organisations, which will be accelerated by upcoming catalysts For personal use only • We attend leading conferences in our sector, to tell our story and open new discussions • Following on from multiple events earlier this
Slide 14: Compelling Clinical Data: CYP-001 for aGvHD
For personal use only Compelling Clinical Data: CYP-001 for aGvHD
Slide 15: CYP-001: Two Nature Medicine publications
CYP-001: Two Nature Medicine publications • CYP-001 has been granted Orphan Drug Designation by the US FDA for the treatment of GvHD • Phase 1 trial of CYP-001 was the first completed For personal use only clinical trial worldwide with any iPSC-derived product 14 1. CYP-001 is Cynata’s Cymerus iPSC-
Slide 16: CYP-001 vs other treatments in SR-aGvHD
CYP-001 vs other treatments in SR-aGvHD CYP = CYP-001 in Phase 1 trial (NCT02923375) Overall Response Overall Response Overall Survival Rux = ruxolitinib in Phase 3 trial (NCT02913261) at Day 28 at Day 56-601 at 18 months (ruxolitinib is now approved for SR-aGvHD) BAT = “best available therapy” cont
Slide 17: CYP-006TK for DFU
For personal use only CYP-006TK for DFU
Slide 18: CYP-006TK – a novel topical MSC product
CYP-006TK – a novel topical MSC product • CYP-006TK utilises a For personal use only iPSC-derived MSCs proprietary surface-coating, optimised for the delivery of MSCs directly to the wound bed • Technology exclusively licenced to Cynata by Tekcyte Limited (agreement for Cynata to acquire this IP out
Slide 19: DFU Phase 1 clinical trial – initial data
DFU | Phase 1 clinical trial – initial data Product: CYP-006TK (topical Cymerus MSC wound dressing) • Ongoing trial in non-healing diabetic foot ulcer (DFU) • Patients randomised to receive standard of care (SoC) or CYP-006TK for 4 weeks, followed by SoC For personal use only • In the first 16 patie
Slide 20: Outlook
For personal use only Outlook
Slide 21: Upcoming catalysts
Upcoming catalysts* Results of three randomised controlled clinical trials expected between late 2024 and early 2026 Phase 1/2 First Results For personal use only kidney patient (Cohort 1) transplant enrolled Phase 2 Enrolment Results aGvHD complete Completion Phase 1 Results Results of enrolment DF
Slide 22: Summary
Summary Next generation stem • Leading platform technology in burgeoning stem cell sector cell company • Diverse and highly credentialed leadership team with proven experience For personal use only • Cymerus manufacturing technology protected by robust patent portfolio Scalable manufacturing • Enabl
Slide 23: Contact Us
For personal use only Contact Us Cynata Therapeutics Limited Level 3, 100 Cubitt Street Cremorne Victoria 3121 Australia cynatatherapeutics info@cynata.com @cynatastemcells www.cynata.com cynata-therapeutics
Cynata Therapeutics — Investor Presentation (September 2024) on 6ix